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epidemiology
In the early 1900s lung cancer was reported to be rare in
women, but has, starting from the 1960s, progressively reached
epidemic proportion, surpassing breast cancer in 1987 and
becoming the leading cause of cancer deaths among women.
Over the past 30 years there has been a four-fold increase in
lung cancer in women (altering the male/female ratio of the
disease) and it is estimated that this rise will not plateau until
after 2010 [1]. Observational studies suggest differences in the
histologic presentation [2–4] and age distribution of lung
cancer between men and women (Table 1). Lung cancer kills
more women in the United States each year than in any other
country in the world: over 170 000 patients die from lung
cancer and over 70 000 are women (29% of all cancer
deaths), that means more deaths than breast, ovarian and
uterine cancer combined together. Small cell lung cancer and
adenocarcinoma are more common in women than in men
(26.6% vs. 19.9%, P <0.001 and 21.6% vs. 9.6%, P <0.001, and
younger lung cancer patients are more likely to be female
than male (age <50 years: 23.3% vs. 12%, P <0.001) [4].
risk factors
Controversy exists as to whether women are more or less
sensitive to the carcinogenic effect of tobacco smoke. Several
case-control studies seem to suggest that women are more
vulnerable to tobacco carcinogens than men. In 1993, Risch
et al. investigated the male–female differences in more than
800 patients with lung cancer and they showed that,
compared with a non-smoking population, the relative risk of
developing lung cancer was 27.9 in women vs. 9.6 in men at
the same level of lifelong exposure (40 pack-year) [5]. An
American Health Foundation case-control study including
1108 men with lung cancer, 781 women with lung cancer
and 2070 controls, found that, given the same level of
exposure to cigarette smoke, women had approximately
1.5-fold higher estimated relative risk of developing lung
cancer than men. The sex difference, in estimated relative
risk, was statistically-significant for all histological subtypes of
lung cancer although slightly greater for adenocarcinoma and
small cell lung cancer than for squamous cell carcinoma [6].
On the contrary, cohort studies have reported that there are
no significant differences in susceptibility between females
and males [7].
However, important differences exist between the sexes:
women who smoke are more likely to develop an
adenocarcinoma, and never-smoking females are more likely
to develop lung cancer than men who have never smoked.
Several studies showed that women may be more predisposed
to molecular aberrations caused by the carcinogenic effects of
tobacco smoke. Kure et al. found a higher frequency of
G:C/T:A mutation in the p53 gene and a higher average of
DNA adduct level in lung tumors from women even if the
level of exposure to carcinogens was lower among women
than men [8]. In the lung of female smokers an increased
expression of the CYP1A1 gene has been found [9]; the
CYP1A1 gene codes for an enzyme (phase 1 enzyme) that
metabolizes the polycyclic aromatic hydrocarbons and leads
to DNA forming adducts. Although the CYP1A1 gene
activates carcinogens metabolically, phase 2 enzymes compete
with phase 1 to inhibit the formation of free radicals. The
most common polymorphism, in phase 2 detoxification
enzymes, is the glutathione S-transferase M1 (GSTM1) null
genotype, which is present in 40 to 60% of the general
population owing to a gene deletion. Expression of the null
phenotype may be a marker of susceptibility to lung cancer, and
the effects of GSTM1 gene deletion may be heightened among
female smokers: the effects of polymorphisms in both genes
could contribute to an increase risk of lung cancer in women
[10]. However, women may have other underlying
predispositions to lung cancer: they appear to have lower
DNA repair capacity and K-ras mutations are more common
in NSCLC from female than from male smokers [11]. The
gastrin-releasing peptide (GRP) is a bombesin-like peptide
which stimulates cell proliferation through an interaction
with its receptor (GRPR). The gene for GRPR is X-linked,
located on chromosome Xp22, near a cluster of genes that
escape X-inactivation. Therefore, women can have two
actively transcribed alleles of the GRPR gene compared with
only one in men. Shiver and colleagues reported that the
GRPR mRNA expression was observed in airway cells and
tissues more frequently in female than male nonsmokers
(55% vs. 0%) and short-term smokers (1–25 pack-years)
(75% vs. 20%) (P =.01) [12]; in addition, the activation of the
GRPR gene occurs earlier in women in response to tobacco
exposure. The same author also showed an increase in the
GRPR gene expression when human airway cells were exposed
to estrogens, suggesting a role in lung carcinogenesis for these
hormones. Stabile and colleagues have shown that b-Estradiol
induced proliferation of cultured non small cell lung cancer
cells and that anti-estrogens could block these effects [13].
Taioli and Wynder [14] also presented evidence that estrogens
may play a role in the development of lung adenocarcinoma
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in women. Using case-control data they showed that: (i) early
age and menopause (40 years or younger) is associated with
reduced risk of adenocarcinoma of the lung ([Odd Ratio]
OR=0.3); (ii) the use of estrogen replacement therapy is
associated with a higher risk of adenocarcinoma of the lung
(OR=1.7); (iii) a positive interaction between estrogen
therapy, smoking, and development of adenocarcinoma of
the lung (OR=32). (iv). The estrogen-related effects in the
lung might be mediated mainly through the functional
estrogen receptor ERb.
More recently, activating mutations in the tyrosine kinase
domain of the Epidermal Growth Factor Receptor (EGFR) have
been identified; these mutations correlate with the radiological
response to Tyrosine-kinase Inhibitors (TKIs) such as gefitinib
and erlotinib. These mutations often occurred in tumors from
non-smoker females with adenocarcinoma [15]. Some authors
observed that the EGFR protein expression is down-regulated in
response to estrogen and up-regulated when estrogen is
depleted, suggesting a cross-talk between these two pathways.
The potential role of estrogens in lung cancer tumorigenesis is
intriguing and should be further investigated.
It is still unclear if lung cancer in women has intrinsic
behaviour and a natural history different from men: however,
women having lung cancer experienced better survival time in
comparison with men. This has important implications in the
design and interpretation of clinical trials where females are
more and more represented. Sex migration could be confusing
even in carefully designed clinical trials and a stratification by
sex could be necessary in the next future.
therapeutic outcomes
The 5-year survival rate for women who have lung cancer is
15.6% compared with 12.5% for men and this improved
survival has important implications in the design and
interpretation of lung cancer trials. From 1990 to 2003 there was
a 60% increase in the number of new cases of lung cancer in
American women, while the number of men diagnosed with
lung cancer remained stable. This increase was reflected in
clinical trial participation by women, causing a survival
improvement and suggesting the need of stratification by sex
in future studies.
Women have superior responses to therapy regardless of
stage, therapeutic modalities or histology (Tables 2 and 3). A
Surveillance analysis among 31.226 patients published in 1998
showed the female sex as favourable prognostic factor. Among
20 561 patients in the Polish cancer registry from 1995 to 1998
women had an RR of death of 1, compared to 1.21 (P = 0.001) in
male by univariate analysis [4]. In a French cohort of 208
patients, when the data was adjusted for stage, women lived
significantly more at each stage [16]. In a retrospective review
of 7553 patients treated for NSCLC between 1974 and 1998
there is an overall median survival of 12.4 months for women
and 10.3 for men (P <0.001) and the advantage is present for
all stages (P <0.001) [17]. In the evaluation of the above
mentioned three studies, two factors have to be taken into
account: the lack of information about smoking habit and
lack of data about cause-specific mortality. However there is
a prospective trial which confirms the female sex as an
independent predictor of survival including in the
multivariate analysis age at diagnosis, histology, stage,
smoking attitude and treatment and, despite the greater
number of comorbidities in the male cohort, the survival was
not negatively impacted for men [18].
In localized NSCLC women will experience superior
survival after either surgical resection or radiation as single
modalities. In a retrospective study done by de Perrot et al.,
women had an hazard ratio of 0.72 (95% CI, 0.56–0.92)
among 1046 patients who underwent surgery for NSCLC from
1977 to 1996. In this analysis the rate of pneumonectomy was
higher in men (32% vs. 22%), but the difference in mortality
was not statistically significant and this fact confirm that early
operative deaths are not the cause of lower survival in men [19].
Another retrospective analysis done by Ferguson et al.
showed a median survival of 41.8 months in women versus
26.9 months in men (P = 0.007) among 451 cases resected
and this gap was particularly present for stage I disease
(109.8 months vs. 50.3 months, P = 0.0008) [20].
In United Kingdom a prospective analysis among 833
patients undergoing lung resection between 1990 and 2000
showed a 5 year survival of 48% in women compared with
36.5% in men (P = 0.01) and this survival advantage was
maintained also considering the higher prevalence of
cardiovascular comorbidities in men that are not entirely
responsible for lower survival [21].
Similar results are reported in the adjuvant setting. At
equivalent stages of lung cancer, women live longer than men. In
the Adjuvant Lung Project Italy (ALPI) trial there was no
advantage for patients randomized to chemotherapy
(mitomycin-vindesine.cisplatin), but there was an advantage in
term of overall survival in favour of female sex [22].
Female sex is an independent positive prognostic factor also
in the SWOG study of multimodality therapy (chemotherapy,
radiotherapy, surgery) : the median survival for women was
21 months vs. 12 months for men (P = 0.08) [23].
In advanced disease there is evidence of survival advantage for
women described in a large review of 13 SWOG trials with
a database of 2531 women enrolled between 1974 and 1987.
Median survival ratio for females/males was 5.7/4.8 with 1-year
survival rates of 19% vs. 14% (P < 0.01) [24]. Similar results
were reported by the European Lung Cancer Working Party
(ELCWP) among 1052 patients evaluating 23 pretreatment
variables: female sex was one of eight variable significantly
associated with superior survival [25].
Similar outcomes emerge for small cell lung cancer: the
analysis of four consecutive prospective trials showed the
superior survival for women compared with men [26]. A total of
2580 patients from 10 SWOG trials with limited (LD) and
Table 1. Distribution of lung cancer by histology and gender
Histologic type Males n = 1156 Females n = 831
Squamous/epidermoid 397 (34%) 165 (20%)
Small-cell 182 (16%) 142 (17%)
Large-cell 111 (10%) 90 (11%)
Adenocarcinoma 418 (36%) 384 (46%)
Brocho-alveolar 17 (1.5%) 30 (3.6%)
symposium article Annals of Oncology
ii80 | Novello & Baldini Volume 17 | Supplement 2 | March 2006
Downloaded from https://academic.oup.com/annonc/article-abstract/17/suppl_2/ii79/131972
by University of Torino user
on 30 August 2018
extensive disease (ED) were analyzed for prognostic factors and,
only for LD, female sex (P £ 0.0.001) was significant favourable
independent predictor [27].
Many data regarding epidermal growth factor receptor
tyrosine kinase inhibitors are in favour of female sex. In second
line therapy the studies IDEAL 1 and 2 evaluated gefitinib in
patients with advanced non-small cell lung cancer previously
treated with one or two lines of chemotherapy and showed
the female sex as predictor of improved outcomes [28, 29]. In
the IDEAL 2 in 50% of women there was an improvement of
symptoms compared with 31% in men and eighty-two
percent of partial response occurred in women. The improved
prognosis observed in women may be due to differences in
frequency of mutations in tyrosine kinase domain of the
epidermal growth factor receptor: 20% in women versus 9%
in men [30].
In broncho-alveolar carcinoma gefitinib is more effective in
women as demonstrated in a SWOG study in which 138
patient with bronchoalveolar carcinoma were treated with
gefitinib as first or second line. In this trial there was a
prolonged survival in females with a statistical significance
in the previously untreated population (P = 0.04) [31].
conclusion
Lung Cancer is not only a man’s disease. Women do not realize
this fact because their awareness of other cancers (e.g. breast
cancer) is much higher. We have to try to help them to
understand that lung cancer is their top cancer killer. Over
20 000 patients diagnosed with lung cancer each year have never
smoked. Of these lung cancer patients, a disproportionate
number are women.
AIDACP (Associazione Italiana Donne anti Cancro del
Polmone) has been set up an initiative among professionally
invoved women (namely doctors, social workers, nurses and
others involved in thoracic oncology), sharing the peculiar
issues of the neoplastic disease in women and facilitating the
possibility to gather together all women who believe it is
important to put their ideas into practice in an association that
can serve to disseminate information in our country and
transfer the data within the context of programmes and social
initiatives of pragmatic intervention.
Another European association is in the planning stage
following a similar association, that already exists in the United
States, called Women Against Lung Cancer (WALC). This is
a non-profit organization of leading scientists, physicians,
nurses and advocates dedicated to treat lung cancer as
a public health threat to women. From a Spanish and Italian
idea we are planning to create a European Group named
WALCE (Women Against Lung Cancer in Europe). We
would like WALCE to represent a valid working tool aimed
at supporting, both socially and scientifically, a challenge
that we cannot miss.
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